Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

High-density lipoprotein and coronary heart disease: current and future therapies.

Natarajan P, Ray KK, Cannon CP.

J Am Coll Cardiol. 2010 Mar 30;55(13):1283-99. doi: 10.1016/j.jacc.2010.01.008. Review.

2.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Heart. 2008 Jun;94(6):706-14. doi: 10.1136/hrt.2007.125401. Review.

PMID:
18480348
3.

Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes.

Viles-Gonzalez JF, Fuster V, Corti R, Badimon JJ.

Curr Opin Cardiol. 2003 Jul;18(4):286-94. Review.

PMID:
12858127
5.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
6.

High-density lipoprotein cholesterol and coronary heart disease.

Young CE, Karas RH, Kuvin JT.

Cardiol Rev. 2004 Mar-Apr;12(2):107-19. Review.

PMID:
14766026
7.

Treatment options for low high-density lipoproteins.

Hafiane A, Kellett S, Genest J.

Curr Opin Endocrinol Diabetes Obes. 2014 Apr;21(2):134-9. doi: 10.1097/MED.0000000000000049. Review.

PMID:
24535232
8.

High-density lipoproteins: multifunctional vanguards of the cardiovascular system.

Marcil M, O'Connell B, Krimbou L, Genest J Jr.

Expert Rev Cardiovasc Ther. 2004 May;2(3):417-30. Review.

PMID:
15151487
9.

What is the most effective strategy for managing diabetic dyslipidaemia?

Reasner CA.

Atheroscler Suppl. 2005 Sep;6(3):21-7. Review.

PMID:
16054442
10.

Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.

Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.

J Cardiovasc Pharmacol. 2008 Apr;51(4):331-51. doi: 10.1097/FJC.0b013e318165e2e7. Review.

PMID:
18427276
11.

Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport.

Hersberger M, von Eckardstein A.

Handb Exp Pharmacol. 2005;(170):537-61. Review.

PMID:
16596814
12.

When high is low: raising low levels of high-density lipoprotein cholesterol.

Toth PP.

Curr Cardiol Rep. 2008 Nov;10(6):488-96. Review.

PMID:
18950560
13.
14.

Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.

Chrysant SG, Ibrahim M.

J Clin Hypertens (Greenwich). 2006 Jul;8(7):493-9; quiz 500-1. Review.

15.

Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.

Shah PK.

Eur Heart J. 2007 Jan;28(1):5-12. Epub 2006 Nov 22. Review.

PMID:
17121756
16.

Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.

Chapman MJ.

Pharmacol Ther. 2006 Sep;111(3):893-908. Epub 2006 Mar 29. Review.

PMID:
16574234
17.

High-density lipoprotein cholesterol and the role of statins.

Chong PH, Kezele R, Franklin C.

Circ J. 2002 Nov;66(11):1037-44. Review.

18.

High-density lipoprotein particles, coronary heart disease, and niacin.

Asztalos BF.

J Clin Lipidol. 2010 Sep-Oct;4(5):405-10. doi: 10.1016/j.jacl.2010.08.012. Epub 2010 Aug 19.

PMID:
21122684
19.

The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.

Cardenas GA, Lavie CJ, Cardenas V, Milani RV, McCullough PA.

Rev Cardiovasc Med. 2008 Fall;9(4):239-58. Review.

PMID:
19122582
20.

Optimal therapy of low levels of high density lipoprotein-cholesterol.

Kashyap ML, Tavintharan S, Kamanna VS.

Am J Cardiovasc Drugs. 2003;3(1):53-65. Review.

PMID:
14727946

Supplemental Content

Support Center